Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
1.75 USD +1.16% Intraday chart for Spero Therapeutics, Inc. -0.57% +19.05%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q4 Revenue $73.5M, vs. Street Est of $18.6M MT
Spero Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tamara Joseph Steps Down as Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc, Effective as of March 6, 2024 CI
Spero Therapeutics Says It Has Enough Funds to Continue Operations Into Late 2025 MT
Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections CI
Transcript : Spero Therapeutics, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q3 Revenue $25.5M, vs. Street Est of $15M MT
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Spero Therapeutics Appoints Esther Rajavelu Chief Financial Officer MT
Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer CI
Spero Therapeutics, Inc. Announces Chief Financial Officer Changes CI
HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating MT
Transcript : Spero Therapeutics, Inc., Q2 2023 Earnings Call, Aug 10, 2023
Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q2 Revenue $2.7M, vs. Street Est of $1.08M MT
Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Spero Therapeutics Shares Rise 14% After Special Protocol Assessment Agreement With FDA DJ
Spero Therapeutics in Special Protocol Assessment Agreement for Phase 3 Trial of Tebipenem HBr DJ
Spero Therapeutics Announces Special Protocol Assessment Agreement with Fda for Phase 3 Pivot-Po Trial of Tebipenem Hbr CI
Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell 3000E Growth Index CI
Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from Russell Microcap Value Index CI
Spero Therapeutics, Inc.(NasdaqGS:SPRO) added to Russell Microcap Growth Index CI
Spero Therapeutics, Inc.(NasdaqGS:SPRO) dropped from Russell 3000E Value Index CI
Spero Therapeutics Names Satyavrat Shukla Chief Executive MT
Chart Spero Therapeutics, Inc.
More charts
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant (MDR) bacterial infections, and rare diseases where there is unmet medical and patient need. Its lead product candidate, tebipenem pivoxil hydrobromide (tebipenem HBr) is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. Its pipeline also includes SPR720 and SPR206. SPR720 is designed to be the oral treatment for non-tuberculous mycobacterial (NTM) infection. SPR206 is a direct acting intravenous (IV)-administered polymyxin analogue developed from its potentiator platform to treat MDR Gram-negative bacterial infections in the hospital setting.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.75 USD
Average target price
7.5 USD
Spread / Average Target
+328.57%
Consensus
  1. Stock
  2. Equities
  3. Stock Spero Therapeutics, Inc. - Nasdaq
  4. News Spero Therapeutics, Inc.
  5. Evercore ISI Upgrades Spero Therapeutics to Outperform From In-Line